What is Melphalan-prednisone-bortezomib (VMP or MPB)?

Category: Prescription Drugs

false

See also: Bortezomib Melphalan

Melphalan-prednisone-bortezomib, also known as VMP or MPB, is a regimen that may be used for the treatment of multiple myeloma in patients that are not candidates for a stem cell transplant. It contains the anticancer agents bortezomib and melphalan along with prednisone, a corticosteroid.

Side effects

Side effects as an overall problem

Side effects as an overall problem
Severity Evaluations
Severe 1
Moderate 1
Mild 0
None 2

Commonly reported side effects and conditions associated with Melphalan-prednisone-bortezomib (VMP or MPB)

Side effect Patients
Peripheral neuropathy 2
Dizziness with hypotension upon standing 1
Weight gain 1

Why patients stopped taking Melphalan-prednisone-bortezomib (VMP or MPB)

Multiple reasons could be selected

Reason Patients
Side effects too severe 3
Change in health plan coverage 1
Did not seem to work 1
Doctor's advice 1
Other 1
See all 4 patients who've stopped taking Melphalan-prednisone-bortezomib (VMP or MPB)

Duration

Stopped taking Melphalan-prednisone-bortezomib (VMP or MPB)

Duration Patients
1 - 6 months 1
6 months - 1 year 3
Adherence
Adherence Evaluations
Always 2
Usually 0
Sometimes 0
Never taken as prescribed 2
Burden
Burden Evaluations
Very hard to take 0
Somewhat hard to take 0
A little hard to take 2
Not at all hard to take 2
Cost per month
Cost per month Evaluations
$200+ 0
$100-199 0
$50-99 0
$25-49 0
< $25 2
Not specified 2

What people switch to and from

Patients stopped taking Melphalan-prednisone-bortezomib (VMP or MPB) and switched to:

Treatment Patients
Methotrexate (Apo-Methotrexate) 1
Last updated:
There are no evaluations for Melphalan-prednisone-bortezomib (VMP or MPB).